Open AccessDiffuse alveolar haemorrhage as a rare complication of antiphospholipid syndrome
Author(s) -
Seth Ishith,
Bhagavata Srinivasan Shyam Prakaash,
Bulloch Gabriella,
Yi Dong Seok,
Frankel Anthony,
Hsu Kelvin,
Passam Freda,
Garsia Roger,
Corte Tamera J.
Publication year - 2022
Publication title -
respirology case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.304
H-Index - 9
ISSN - 2051-3380
DOI - 10.1002/rcr2.948
Subject(s) - medicine , diffuse alveolar hemorrhage , complication , rituximab , antiphospholipid syndrome , methylprednisolone , cyclophosphamide , intravenous immunoglobulins , surgery , chemotherapy , thrombosis , lymphoma , antibody , immunology
Abstract Diffuse alveolar haemorrhage (DAH) is a rare complication of antiphospholipid syndrome. With a mortality rate of 46%, early diagnosis and management remain an ongoing challenge. Case reports are limited, and management guidelines are not yet definitive. In this case report, we present a 43‐year‐old male with DAH who required high‐dose oral steroids, intravenous methylprednisolone cyclophosphamide and rituximab over 18 months to control life‐threatening episodes of pulmonary bleeding.